A big challenge for innovations over the years had been in relation to the issues relating to the pre-grant oppositions of Patents. Under Indian law, a pre-grant opposition
The IPAB allowed an appeal and granted a patent related to the pharmaceutical composition of coenzyme Q10 to the University of Miami. The application claims were directed to pharmaceutical composition
Background: The suit was filed in the Delhi Court by the UK-based biopharmaceutical company AstraZeneca against Dr Reddy’s Laboratories Ltd to prevent them from launching the generic version
Archana Shanker and Devinder Singh Rawat talk about the key policy shifts proposed by the National Health Policy 2017, and the regulation of the pharmaceutical-healthcare relationship. Excerpts
CIC rejects reply of CDSCO under RTI Act refusing to divulge information, “for want of any concrete reasoning.” The appellant approached the Central Information Commission (CIC) when the
Pravin Anand has been invited to deliver the keynote address at the Healthcare – Pharma and Medical Devices Summit being held on August 4th in Mumbai. Organised by
India has been in the centre of IP debate worldwide quite often and now another issue seemingly is making an entry i.e. Section 4 of the Indian Patents
Pravin Anand and Archana Shanker look at the regulatory framework governing India’s pharmaceutical market. India, the largest democracy in the world, has rightly been termed the ‘pharmacy of
Neeti Wilson speaks on ‘Patents, Innovation and Access to New Pharmaceuticals’ at the National Conference on IPR in Health Sciences organised by Amity University. The two day conference,
Archana Shanker and Devinder Singh Rawat discuss the interaction between the healthcare and pharmaceutical industries in India, especially on aspects related to advertising, pricing and regulatory, prefaced on
